Frederick Lansigan, MD | Find a ...

Dr. Frederick LANSIGAN, MD

Claim this profile

Dartmouth Hitchcock Medical Center

Studies Lymphoma
Studies Large B-Cell Lymphoma
12 reported clinical trials
31 drugs studied

Area of expertise

1

Lymphoma

Frederick LANSIGAN, MD has run 5 trials for Lymphoma. Some of their research focus areas include:

13q positive
13q negative
12 positive
2

Large B-Cell Lymphoma

Frederick LANSIGAN, MD has run 4 trials for Large B-Cell Lymphoma. Some of their research focus areas include:

CD20 positive

Affiliated Hospitals

Image of trial facility.

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Image of trial facility.

Dartmouth-Hitchcock Medical Center

Clinical Trials Frederick LANSIGAN, MD is currently running

Image of trial facility.

Rituximab vs Mosunetuzumab

for Follicular Lymphoma

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.

Recruiting

2 awards

Phase 3

13 criteria

Image of trial facility.

Venetoclax + Obinutuzumab

for Leukemia

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.

Recruiting

2 awards

Phase 3

1 criteria

More about Frederick LANSIGAN, MD

Clinical Trial Related

6 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Frederick LANSIGAN, MD has experience with

  • Rituximab
  • Nivolumab
  • Cyclophosphamide
  • Doxorubicin Hydrochloride
  • Lenalidomide
  • Obinutuzumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Frederick LANSIGAN, MD specialize in?

Is Frederick LANSIGAN, MD currently recruiting for clinical trials?

Are there any treatments that Frederick LANSIGAN, MD has studied deeply?

What is the best way to schedule an appointment with Frederick LANSIGAN, MD?

What is the office address of Frederick LANSIGAN, MD?

Is there any support for travel costs?